CORONAVAC TRIAL KICKS OFF
History was made at the Sefako Makgatho Health Science University in Pretoria on Friday when the first two children – aged between 12 and 17 – received the first of two CoronaVac jabs at the university’s MeCRU Clinical Research Unit.
The doses of vaccine will be given 28 days apart and the study is expected to last between 13 to 14 months. The children are just two out of 2000 South African youths – aged between 6 months and 17 years old – participating in the CoronaVac trial, which has been approved by the South African Health Products Regulatory Authority (SAHPRA) and the World Health Organization (WHO).
Numolux said it has partnered with 7 clinical research sites across South Africa where the vaccinations will take place.
Other children from Chile, the Philippines, Malaysia and Kenya are also participating in the trial. The conditional use of CoronaVac in South Africa was approved in July 2021 by SAHPRA.
“The primary objective of the study is to evaluate the efficacy of two doses of CoronaVac against confirmed symptomatic COVID-19 cases in children and adolescents …efficacy will also be evaluated against hospitalisation and severe COVID-19,” said Sinovac and Numolux on Thursday, 9 September, when the trial was announced in South Africa.